BrainStorm Cell Therapeutics Will Host a Conference Call to Update Shareholders on Recent Company Developments

  BrainStorm Cell Therapeutics Will Host a Conference Call to Update
  Shareholders on Recent Company Developments

Business Wire

NEW YORK & PETACH TIKVAH, Israel -- August 14, 2013

BrainStorm Cell Therapeutics Inc. (OTC.QB:BCLI), leading developer of adult
stem cell technologies for neurodegenerative diseases, today announced that it
will hold a conference call on Tuesday, August 20, 2013 at 8:45 a.m. Eastern
Daylight Time, 15:45 Israel Daylight Time. Mr. Chaim Lebovits, President and
Principal Executive Officer, will update shareholders on the recent public
offering and other company developments. The call will be conducted in
English, with Q&A in both English and Hebrew.

Callers may participate in the conference call by dialing:

USA:1-888-407-2553
Israel: 03-918-0644
International:+972-3-918-0644

Callers are invited to ask relevant questions in English or Hebrew during the
conference call. Questions may also be pre-submitted
toinfo@brainstorm-cell.com prior to 7:00 a.m. EDT on Monday, August 19, 2013.

A recording of the conference will be available for download Wednesday, August
21, 2013 from the company’s website.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived from
autologous bone marrow cells for the treatment of neurodegenerative diseases.
The Company holds the rights to develop and commercialize its NurOwn
technology through an exclusive, worldwide licensing agreement with Ramot, the
technology transfer company of Tel Aviv University. For more information,
visit the company’s website at www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information
constitute "forward-looking statements" and involve risks and uncertainties
that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking statements.
Terms and phrases such as “may,” “should,” “would,” “could,” “will,” “expect,”
“likely,” “believe,” “plan,” “estimate,” “predict,” “potential,” and similar
terms and phrases are intended to identify these forward-looking statements.
The potential risks and uncertainties include, without limitation, risks
associated with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key executives and
on its scientific consultants; ability to obtain required regulatory
approvals; and other factors detailed in BrainStorm's annual report on Form
10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These
factors should be considered carefully, and readers should not place undue
reliance on BrainStorm’s forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press release.
We do not assume any obligation to update forward-looking statements to
reflect actual results or assumptions if circumstances or management’s
beliefs, expectations or opinions should change, unless otherwise required by
law. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.

Contact:

BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)
Mr. Chaim Lebovits, President
+972-3-9236384
info@brainstorm-cell.com
www.brainstorm-cell.com